- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -
- Agreement leverages Astellas Universal Donor Cell Platform and Adaptimmunes stem-cell derived allogeneic T-cell platform -
- Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products -
TOKYO, PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune. The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell. The collaboration will also utilize Astellas Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.
Adaptimmune has been collaborating with Universal Cells (now an Astellas Company) since 2015 on development of gene-edited iPSC cell lines, for which Adaptimmune has rights to develop and commercialize resulting T-cell therapy products using its proprietary process for generating T-cells from stem cells without the use of feeder cell lines.
Astellas will fund research up until completion of a Phase 1 trial for each candidate. Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out. The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.
"Astellas positions immuno-oncology as one of its strategic areas of primary focus, and it is engaged in the development of novel therapies for cancer patients using a new modality/technology," stated Naoki Okamura, Representative Director Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer, Astellas. "In addition to NK cells, T-cells are an important component of cell therapy for immuno-oncology, and we look forward that this agreement with Adaptimmune will enable us to create new stem-cell derived allogeneic T-cell therapies for a variety of cancers, including solid tumors, in the future. We will continue to dedicate our efforts in delivering novel treatments for diseases with high unmet medical needs, pursuing cutting-edge science and technological advances.
We are delighted to establish this significant co-development partnership with Astellas, which builds upon and substantially extends an existing collaboration focused on gene editing of iPSC cells, said Helen Tayton-Martin, Adaptimmunes Chief Business Officer and Co-Founder. This new collaboration may encompass both CAR-T and TCR T-cell approaches, including our novel HLA-independent TCR (HiT) platform. It brings together highly complementary skills and expertise across the two organizations, and will enable the accelerated development of new, off-the-shelf T-cell therapy products for people with cancer.
Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently. Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.
Under the terms of the agreement, Adaptimmune may receive up to $897.5 million in payments, including:
In addition, Adaptimmune will receive research funding of up to $7.5 million per year.
Finally, Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.
Under the terms of the agreement, Astellas may receive up to $552.5 million, including:
In addition, Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.
To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally. Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.
The impact of this transaction on Astellas financial results in the fiscal year ending March 31, 2020 will be limited.
About AdaptimmuneAdaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Companys unique SPEAR (Specific Peptide Enhanced Affinity Receptor) Tcell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.
About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en
Adaptimmune Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 6, 2019, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Cautionary Notes Regarding Forward-Looking Statements (Astellas)In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on managements current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Media Relations:Sbastien Desprez VP, Communications and Investor RelationsT: +44 1235 430 583M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. Senior Director, Investor RelationsT: +1 215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
Contacts for inquiries or additional information:Astellas Pharma Inc.Corporate CommunicationsTEL: +81-3-3244-3201 FAX: +81-3-5201-7473
- Ronawk using stem cell tech developed at Olathe lab to advance liver cancer research in Turkey - Startland News - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW - October 5th, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 5th, 2021
- Global Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness -... - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 5th, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 5th, 2021
- Exosome therapeutic Market 2021 is Showing Impressive Growth by 2028 | Trends, Share, Size, Top Key Players Analysis and Forecast Research EcoChunk -... - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - WWNY - October 5th, 2021
- Cell Based Assay & High Content Screening Market Report 2021: The Workhorse of the Pharmaceutical Industry is Becoming a Central Player in... - October 5th, 2021
- Advancing the Development of Innovative Veterinary Products - FDA.gov - October 5th, 2021
- Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial - WBKO - October 5th, 2021
- $500K Grant Supports Research on Muscle Growth in Pigs, With Broader Health Implications - Maryland Today - July 22nd, 2021
- EU approves bluebird bio's CALD gene therapy Skysona - PMLiVE - July 22nd, 2021
- Secrets and pies: the battle to get lab-grown meat on the menu - The Guardian - July 22nd, 2021
- Biomedical Warming and Thawing Devices Market Revenue to Cross USD 308 Mn by 2027: Global Market Insights Inc. - Markets Insider - July 22nd, 2021
- A Recovery for All Of Us: New York City Invests $1 Billion in Life Sciences - Brooklyn Daily Eagle - July 22nd, 2021
- The growing global "infodemic" around stem cell therapies - Axios - June 25th, 2021
- NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Yahoo Finance - June 25th, 2021
- Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies - Yahoo... - June 25th, 2021
- Immusoft Announces Formation of Scientific Advisory Board - Business Wire - June 25th, 2021
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene... - June 25th, 2021
- Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy... - June 25th, 2021
- More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities - PRNewswire - June 25th, 2021
- Andrs Garca Receives Distinguished Professor Award | Research - Research Horizons - June 25th, 2021
- Local foundation awards $1.25 million to MIND Institute to study rare genetic condition - UC Davis Health - June 25th, 2021
- MeCP2 is a microsatellite binding protein that protects CA repeats from nucleosome invasion - Science Magazine - June 25th, 2021
- The Stem Cell Manufacturing market is projected to reach USD 18.0 billion by 2026 from USD - GlobeNewswire - May 28th, 2021
- Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic... - May 28th, 2021
- Global Flow Cytometry Market (2020 to 2026) - by Technology, Product and Service, Application, End-user and Geography - ResearchAndMarkets.com -... - May 28th, 2021
- Meso-Brain project explores 3D printed stem cells to treat neurological conditions - 3D Printing Industry - May 28th, 2021
- Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day - Business Wire - May 28th, 2021
- GPB Scientific Announces Additional Growth Financing to Support Commercialization of Curate Cell Processing System for Next-Generation Cell & Gene... - May 28th, 2021
- TScan Therapeutics Adds to Executive Leadership Team and Board of Directors - BioSpace - May 28th, 2021
- Bone Therapeutics Provides First Quarter 2021 Business Update - GlobeNewswire - May 28th, 2021
- Merakris Therapeutics, Inc. Announces FDA Clearance for - GlobeNewswire - May 28th, 2021
- Stem Cell Manufacturing Market 2021 | Research With Size, Growth, Manufacturers, Key Segment, Analysis, Development Status, Segments and 2027... - February 19th, 2021
- Tissue regeneration: Reserve or reverse? - Science Magazine - February 19th, 2021
- Global Scaffold Technology Market Is Expected to Reach USD 2.16 billion by 2028 : Fior Markets - GlobeNewswire - February 19th, 2021
- Recombinant Growth Factors to Account for Over 45% of Overall Demand through 2031: Persistence Market Research - PRNewswire - February 19th, 2021
- The Untapped Potential of Cell and Gene Therapy - AJMC.com Managed Markets Network - February 19th, 2021
- Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey -... - February 19th, 2021
- Cell Therapy Processing Market To Grow Value $12062 Million By 2026 | Latest Research Report - PharmiWeb.com - February 19th, 2021
- Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel... - February 19th, 2021
- Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market - BioSpace - February 19th, 2021
- Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PRNewswire - February 19th, 2021
- Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,... - February 19th, 2021
- Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer... - February 19th, 2021
- Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,... - February 19th, 2021
- How Irish medtech came to thrive - Med-Tech Innovation - February 19th, 2021
- Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period - BioSpace - February 11th, 2021
- Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines - Business Wire - February 11th, 2021
- Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies - PRNewswire - February 11th, 2021
- Global Biopreservation Market Is Expected to Reach USD 7.67 Billion by 2028 : Fior Markets - GlobeNewswire - February 11th, 2021
- Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater... - February 11th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 11th, 2021
- 2020 Outlook on the Global Singlecell Technology Industry - Market Size was Over $800 Million in 2019 - ResearchAndMarkets.com - Business Wire - February 11th, 2021
- Stem Cell Cryopreservation Equipments Market Size Report: Strategies of Key Manufacturers, Project Investment of New Industries: Chart, Worthington... - February 11th, 2021
- Seattle Cancer Care Alliance Celebrates 20 Years of Innovation in Cancer Treatment and Care - Business Wire - February 11th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 11th, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- Biobanking Market Report Research and Global Outlook 2021 to 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - February 7th, 2021
- Animal Stem Cell Therapy Market By Product Type (Dogs, Horses) And By End-Users/Application (Veterinary Hospitals, Research Organizations) Market... - February 6th, 2021
- Stem Cell Assay Market Share, Demand, Manufacturers and Forecast till 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent... - February 6th, 2021
- Global Apoptosis Assays Market Set To Grow At Healthy CAGR Of 11.10% By 2027||Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG, Biotium,... - February 6th, 2021
- Jill Biden signals White House resolve on cancer research: This is the fight of our lives - The Cancer Letter - February 6th, 2021
- Tiny sensor technique reveals cellular forces involved in tissue generation - Brown University - February 6th, 2021
- Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,... - February 6th, 2021
- Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive - February 6th, 2021
- Stem Cell Market is Expected to Grow with an Impressive CAGR till 2027 | Players Vcanbio, Boyalife, Beikebiotech KSU | The Sentinel Newspaper - KSU... - February 6th, 2021
- Regenerative Medicine Market to be Valued at USD 6.49 Billion by 2027 | The Escalating Burden of Chronic Diseases and Genetic Aberrations will be the... - February 4th, 2021
- Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology - PRNewswire - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - Yahoo Finance UK - February 4th, 2021
- Biobanks Market | Prominent Factors Analysis that will Help in Reshaping the Market Growth - BioSpace - February 4th, 2021
- Alexion Reports Fourth Quarter and Full Year 2020 Results - BioSpace - February 4th, 2021
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Size, Share, Analysis, Growth Driver and Industry Segments by 2027 KSU | The... - February 4th, 2021
- Transfection Technologies Market Size 2020 | Global Business Strategies, Growing CAGR of 20.0%, Industry Revenue, Opportunities-Aldrich Co Thermo... - February 4th, 2021
- Global Apoptosis Assays Market Report 2020: Apoptosis Assay Kits Lead the Demand with 42.5% Share - Forecast to 2026 - GlobeNewswire - February 4th, 2021
- Global Hematopoietic Stem Cells Transplantation Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025 KSU | The Sentinel... - February 4th, 2021
- Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID) - GlobeNewswire - February 4th, 2021
- Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell... - February 4th, 2021